Active surveillance as a management strategy for favourable-risk prostate cancer has increased in recent years, in an effort to prevent the adverse effects associated with unnecessary overtreatment of low-risk disease. However, long-term data have, in the past, been lacking, making it difficult to assess the effectiveness of this approach. In this Review, Tosoian et al. discuss the current state-of-the-art in active surveillance, reviewing the available evidence and considering future directions in the field.
- Jeffrey J. Tosoian
- H. Ballentine Carter
- Stacy Loeb
